What is the market price of adagrasib in 2024?

Adagrasib (Adagrasib) is an oral small molecule inhibitor of KRAS G12C and has been extensively developed in the fields of monotherapy and combination therapy. The product, discovered by Mirati Therapeutics (Bristol-Myers Squibb), has been studied in the Phase 1/2 Krystal-1 clinical trial in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors. In December 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasiib as a targeted therapy for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy, sold under the trade name KRAZATI.

The original drug of adagrasibu is not currently on the market in China, so it cannot be included in medical insurance. Patients can only purchase the drug through overseas channels. The U.S. original research version Adagrasib sold overseas, Specifications200mg*180 tablets, is priced at more than 100,000 yuan per box (the price may fluctuate due to exchange rates), which is very expensive. According to the latest news, the first generic drug of adagrasibu has been developed and sold overseas. Its pharmaceutical ingredients are basically the same as those of the original drug. The manufacturer is Laos Lucius Pharmaceutical Factory. Specifications The price of each box of 200mg*90 tablets is more than 4,000 yuan (the price may fluctuate due to the exchange rate), which is much cheaper than the price of the original drug. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.